Abstract:Hydrogel microspheres with probiotic‐loaded therapy have been considered an effective and safe strategy for treating inflammatory bowel disease (IBD). However, the low survival rate under harsh stomach conditions and inflam‐matory cytokine target release efficiency remains a major challenge for their application. Herein, a novel NO‐responsive poly‐γ‐glutamic acid (γ‐PGA) hydrogel microcapsule (NRPM) strategy based on a droplet microfluidic technology platform is proposed. Accordingly, highly uniform microspheres with high cell densities (6.0 × 108 cells mL−1) and a wide range of diameters (100–600 μm) are produced, which are critical for realizing accurate down‐stream evaluation and applications. Owing to the cytoprotective effects of the NRPM, the decorated probiotics showed high viability in the simulated gastric (89.67%) and intestinal (93.67%) fluid environments, while the data are 0% and 61.60% for free cells, respectively. Moreover, both in vitro and in vivo studies demonstrate that microspheres can respond to nitric oxide (NO) stimuli and rapidly release probiotics to maintain the intestinal mechanical barrier and regulate the balance of intestinal flora. Consequently, NRPM significantly increases the treatment efficacy against dextran sulfate sodium‐induced colitis in a mouse model. The results demonstrate that NRPM is a promising approach for improving the efficacy of orally administered probiotics in patients with colonic IBD. A novel approach is introduced for the production of NO‐responsive poly‐γ‐glutamic acid hydrogel microcapsule (NRPM) with probiotics encapsulation. Based on the droplet microfluidic technology platform, highly uniform microspheres (300 µm) with high cell densities (6.0 × 108 cells mL−1) are produced. Significantly, it exhibits excellent gastric acid resistance and smart inflammatory factor targeted delivery performance to ameliorate colitis.

Microfluidic-based Multifunctional Microspheres for Enhanced Oral Co-Delivery of Probiotics and Postbiotics

Microfluidics-Derived Microparticles with Prebiotics and Probiotics for Enhanced in Situ Colonization and Immunoregulation of Colitis.

Preparation and synbiotic interaction mechanism of microcapsules of Bifidobacterium animalis F1-7 and human milk oligosaccharides (HMO)

Multishell Colloidosome Platform with Sequential Gastrointestinal Resistance for On-Demand Probiotic Delivery.

Microfluidic Strategies for Encapsulation, Protection, and Controlled Delivery of Probiotics

Responsively Degradable Nanoarmor-Assisted Super Resistance and Stable Colonization of Probiotics for Enhanced Inflammation-Targeted Delivery

Bioinspired core-shell microparticle for dual-delivery of prebiotic and probiotic for the treatment of ulcerative colitis

Prebiotics and Postbiotics Synergistic Delivery Microcapsules from Microfluidics for Treating Colitis.

Carboxymethyl Konjac Glucomannan-Chitosan Complex Nanogels Stabilized Emulsions Incorporated into Alginate As Microcapsule Matrix for Intestinal-Targeted Delivery of Probiotics: in Vivo and in Vitro Studies.

Microfluidic Fabrication of Encapsulated Probiotic Microspheres Using Cysteine-Modified Chitosan with Dual Functions of Bacterial Adhesion and Intestinal Mucosal Adhesion

Antioxidative Single Atomic Nanocatalysts Facilitate Orally Administered Probiotic Inulin Gels for Acute Colitis Amelioration

Bacteria-Induced Colloidal Encapsulation for Probiotic Oral Delivery.

Intracellular hydrogelation of macrophage conjugated probiotics for hitchhiking delivery and combined treatment of colitis

Bioinspired Micro-Nano Hierarchical Delivery System for Sequential Targeted Therapy of Inflammatory Bowel Disease

Microalgal Biomass-Assisted Delivery of Probiotics for Modulation of Gut Homeostasis and Alleviation of Intestinal Inflammation

Poly‐γ‐Glutamic Acid Microgel‐Encapsulated Probiotics with Gastric Acid Resistance and Smart Inflammatory Factor Targeted Delivery Performance to Ameliorate Colitis

Probiotics Armed with In Situ Mineralized Nanocatalysts and Targeted Biocoatings for Multipronged Treatment of Inflammatory Bowel Disease

Micro-ecology restoration of colonic inflammation by in-Situ oral delivery of antibody-laden hydrogel microcapsules

Mucoadhesive probiotic-based oral microcarriers with prolonged intestinal retention for inflammatory bowel disease therapy

Engineering microbial fermentation-based delivery carriers capable of controlling drug release for inflammatory bowel disease therapy

Bioorthogonal conjugation and responsive nanocoating of probiotics for inflammatory bowel disease